Education & Training
- Perkins, K.A., Kunkle, N., & Karelitz, J.L. Threshold dose for behavioral discrimination of cigarette nicotine content in menthol vs. non-menthol smokers. Psychopharmacology, 2017, 234, 1255-1265. DOI: 10.1007/s00213-017-4563-3
- Perkins, K.A., Karelitz, J.L., & Boldry, M.A. Nicotine acutely enhances reinforcement from non-drug rewards in humans. Frontiers in Psychiatry (Addictive Disorders section), 2017, 8, 65. doi: 10.3389/fpsyt.2017.00065. https://doi.org/10.3389/fpsyt.2017.00065. Open access link: http://journal.frontiersin.org/article/10.3389/fpsyt.2017.00065/full
- Perkins, K.A. Procedures for conducting a Crossover Evaluation of Addiction Treatment Efficacy (CREATE) for novel medications in smoking cessation (Manual). University of Pittsburgh, 2013, revised 2016.
- Perkins, K.A. & Lerman, C. (2014) An efficient early Phase 2 procedure to screen medications for efficacy in smoking cessation. Psychopharmacology, 231: 1-11. DOI: 10.1007/s00213-013-3364-6.
- Perkins, K.A., Conklin, C.A., & Levine, M.D. (2008) Cognitive-behavioral therapy for smoking cessation: a practical guide to the most effective treatments New York: Routledge, 2008.
Kenneth Perkins, PhD, Receives Prestigious Division 28 MED Associates Brady-Schuster Award from the American Psychological Association
The Department of Psychiatry is delighted to congratulate Kenneth Perkins, PhD, who has been honored by the American Psychological Association (APA). Dr. Perkins received the APA’s Division 28 MED Associates Brady-Schuster Award, which honors a senior scientist who conducts outstanding research underscoring the fundamental importance of behavioral science to psychopharmacology or substance use disorder . An expert...
Findings by Drs. Kenneth Perkins, Roy Chengappa, and Jessica Gannon Test Novel Compound for Smoking Cessation in Smokers with Schizophrenia
Most smokers want to quit, but most who try ultimately do not succeed, even using therapeutics to aid in cessation. Dozens of cessation medications have been tested for potential efficacy during the past 30 years, yet the FDA has approved only three first-line drugs for this use: nicotine replacement, bupropion, and varenicline. Preclinical research shows that compounds acting at α7 nicotinic receptors (nAChRs) can...